What is Sidoti Csr's Estimate for USNA Q3 Earnings?

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Equities researchers at Sidoti Csr reduced their Q3 2025 earnings estimates for USANA Health Sciences in a research report issued on Wednesday, July 23rd. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings per share of $0.47 for the quarter, down from their prior estimate of $0.65. The consensus estimate for USANA Health Sciences' current full-year earnings is $2.45 per share.

Separately, Wall Street Zen raised USANA Health Sciences from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd.

USANA Health Sciences Trading Down 0.4%

USNA stock traded down $0.13 during midday trading on Friday, reaching $31.97. 175,530 shares of the company's stock traded hands, compared to its average volume of 137,350. The stock's 50-day moving average is $30.86 and its 200 day moving average is $30.11. USANA Health Sciences has a 52-week low of $23.10 and a 52-week high of $45.86. The stock has a market cap of $595.19 million, a P/E ratio of 17.76, a PEG ratio of 1.02 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.20. The company had revenue of $235.85 million during the quarter, compared to the consensus estimate of $225.20 million. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%.

Insider Buying and Selling at USANA Health Sciences

In related news, COO Walter Noot sold 6,291 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $30.29, for a total value of $190,554.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO G Doug Iiekking sold 4,548 shares of USANA Health Sciences stock in a transaction dated Friday, May 9th. The shares were sold at an average price of $29.61, for a total value of $134,666.28. The disclosure for this sale can be found here. Insiders have sold 12,013 shares of company stock valued at $360,149 over the last ninety days. 0.63% of the stock is owned by insiders.

Hedge Funds Weigh In On USANA Health Sciences

A number of large investors have recently bought and sold shares of USNA. PNC Financial Services Group Inc. lifted its holdings in shares of USANA Health Sciences by 339.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock valued at $27,000 after purchasing an additional 771 shares during the last quarter. Versant Capital Management Inc boosted its holdings in USANA Health Sciences by 542.5% during the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock worth $31,000 after buying an additional 971 shares in the last quarter. Parallel Advisors LLC boosted its position in USANA Health Sciences by 8,141.2% during the first quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock worth $38,000 after purchasing an additional 1,384 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in USANA Health Sciences during the fourth quarter worth $83,000. Finally, CWM LLC boosted its holdings in USANA Health Sciences by 109.7% in the 2nd quarter. CWM LLC now owns 2,762 shares of the company's stock worth $84,000 after buying an additional 1,445 shares during the last quarter. Institutional investors own 54.25% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.